OMERACT takes ethics and conflict of interest issues very seriously, and therefore, has developed specific guidelines to which its Executive Committee members are held.
OMERACT is involved with the development and validation of clinical and imaging outcome measures in rheumatic diseases. The results of these processes are widely based and publicly recorded, and have gained the confidence of professional groups, researchers, the pharmaceutical industry and regulatory agencies around the world. Since much of the funding of OMERACT is derived from the pharmaceutical industry, it is important that the committee’s work be independent of sponsor influence and that any perception of its direction by industry or conflict of interest of its members be avoided. Therefore, the members of OMERACT’s committees hereby agree to the following principles: